Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelinesGiacomo Bregni, Francesco Sclafani, Tuğba Akın Telli et al.|Cancer Treatment Reviews|2019Cited by 19
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide populationFederica Lo Prinzi, Monica Niger, Florian Castet et al.|The Oncologist|2024Cited by 10
Negative impact of corticosteroid use on outcome in patients with advanced <scp>BTCs</scp> treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide populationFederica Lo Prinzi, L. Bartalini, Francesca Salani et al.|International Journal of Cancer|2025Cited by 4
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumabChiara Pirrone, Caterina De Grandis, Umberto Malapelle et al.|European Journal of Cancer|2025Cited by 3
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and DurvalumabSilvia Camera, Giovanni Farinea, Lorenzo Fornaro et al.|Targeted Oncology|2026Cited by 1